| HRS-5965 / Jiangsu Hengrui Pharma |
NCT06137768: A Trial of HRS-5965 Tablets in Primary IgA Nephropathy |
|
|
| Not yet recruiting | 2 | 105 | NA | HRS-5965, Placebo | Chengdu Suncadia Medicine Co., Ltd. | Primary IgA Nephropathy | 08/24 | 03/25 | | |
| Recruiting | 2 | 24 | RoW | HRS-5965 tablets | Chengdu Suncadia Medicine Co., Ltd. | Paroxysmal Nocturnal Hemoglobinuria | 12/27 | 12/27 | | |
NCT06051357: Proof of Concept Study to Assess the Efficacy, Safety of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria |
|
|
| Active, not recruiting | 2 | 26 | RoW | HRS-5965 tablets | Chengdu Suncadia Medicine Co., Ltd. | Paroxysmal Nocturnal Hemoglobinuria | 10/24 | 10/24 | | |
NCT05505955: Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency |
|
|
| Recruiting | 1 | 98 | RoW | HRS-5965, Placebo | Chengdu Suncadia Medicine Co., Ltd. | Glomerulonephritis | 04/23 | 04/23 | | |